Myosana Therapeutics has completed a seed funding round totalling over $5 million led by investor John Ballantyne. The capital will go towards developing Myosana’s gene therapy platform for neuromuscular and cardiac disease, with the goal of identifying the first development candidate for Duchenne muscular dystrophy by 2025. “Built on decades of expertise in neuromuscular diseases, […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!